Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLG | P54098 | 2/20 | 0.55 |
| ▸ | NT5E | P21589 | 1/20 | 0.55 |
| ▸ | P2RY2 | P41231 | 7/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | MTOR | P42345 | 1/20 | 0.48 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.48 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.48 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.48 |
| ▸ | P2RY4 | P51582 | 3/20 | 0.48 |
| ▸ | P2RY6 | Q15077 | 3/20 | 0.48 |
| ▸ | ST6GAL1 | P15907 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13173263 | 1.00 | POLG (0.55) | POLGNT5EP2RY2LMNATHRB | |
| SCHEMBL800855 | 1.00 | POLG (0.55) | POLGNT5EP2RY2LMNATHRB | |
| SCHEMBL1274372 | 1.00 | POLG (0.55) | POLGNT5EP2RY2LMNATHRB | |
| SCHEMBL800670 | 1.00 | POLG (0.55) | POLGNT5EP2RY2LMNATHRB | |
| SCHEMBL380557 | 0.90 | NT5E (0.60) | NT5EP2RY2LMNATHRBMTOR | |
| SCHEMBL1763028 | 0.89 | NT5E (0.58) | POLGNT5EP2RY2LMNATHRB | |
| SCHEMBL6672414 | 0.89 | POLG (0.56) | POLGNT5EP2RY2LMNATHRB | |
| SCHEMBL3414689 | 0.89 | NT5E (0.58) | POLGNT5EP2RY2LMNATHRB | |
| SCHEMBL30381145 | 0.89 | POLG (0.54) | POLGNT5EP2RY2LMNATHRB | |
| Ammonia Solution, Strong SCHEMBL1763145 | 0.89 | NT5E (0.57) | POLGNT5EP2RY2LMNATHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012040126-A1 | SUBSTITUTED NUCLEOTIDE ANALOGS | ALIOS BIOPHARMA, INC. (US) | 2012-03-29 | — | — | WO | disclosed |
| US-20120070411-A1 | SUBSTITUTED NUCLEOTIDE ANALOGS | ALIOS BIOPHARMA, INC. (US) | 2012-03-22 | — | — | US | disclosed |
| US-20120070411-A1 | SUBSTITUTED NUCLEOTIDE ANALOGS | ALIOS BIOPHARMA, INC. (US) | 2012-03-22 | — | — | US | disclosed |
| US-20100249068-A1 | SUBSTITUTED NUCLEOSIDE AND NUCLEOTIDE ANALOGS | ALIOS BIOPHARMA, INC. (US) | 2010-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120070411-A1 | SUBSTITUTED NUCLEOTIDE ANALOGS | PNP, NTPCR, NUDT1 | POLG 325/4885NT5E 15/4885P2RY2 101/4885 |
| US-20100249068-A1 | SUBSTITUTED NUCLEOSIDE AND NUCLEOTIDE ANALOGS | PNP, TYMP, NTPCR | POLG 278/4885NT5E 19/4885P2RY2 103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.